PRM72 Model Selection Process for Cost Effectiveness Analysis of an Organized AAA Screening in Austria  by Urach, C. et al.
constant. More recently, it has been argued that a ‘life cycle’ approach should be
routinely applied to technology assessments, including incorporating anticipated
changes in price. Since the results from these different approaches can have im-
portant implications for reimbursement and conditional coverage decisions, it is
critical that rationale and methods for incorporating future changes are more
clearly defined. The aims of this research are to: i) establish the key principles and
assessments related to incorporating future changes when extrapolating cost-ef-
fectiveness results; ii) consider how additional information and analyses could be
used to more appropriately inform a range of policy decisions. METHODS: We
reviewed existing literature investigating future changes in the decision context
due to price, technological developments and the information available to decision
makers to examine their relevance and implications for cost-effectiveness meth-
ods and approaches to extrapolation. A case study evaluating the cost-effective-
ness of biologics for the treatment of psoriatic arthritis is used to demonstrate the
impact of modelling a changing context on both the magnitude and the uncertainty
around cost-effectiveness results. RESULTS: Our results show that incorporating
anticipated changes in the decision context, particularly where decisions made are
irreversible, can have a dramatic effect on the extrapolation of cost-effectiveness
results both in terms of determining the optimal treatment decision and in terms of
characterising the level and consequences of uncertainty around these results.
CONCLUSIONS:A changing decision context can have a significant impact on cost-
effectiveness results and the conclusions drawn from these results. This changing
decision context so far as it can be anticipated should therefore be modelled to
allow us to make the best possible decisions incorporating all available informa-
tion.
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OBJECTIVES: There has been substantial debate on the need for differential dis-
counting for monetary and health gains in economic evaluations. A way to identify
the need for such discounting strategies, is through eliciting the societal time pref-
erences for monetary and health outcomes. In this article we investigate the time
preference for money and health gains through a pilot survey on Dutch university
students. METHODS: Fifty university students completed three questionnaires on
their intertemporal choices for quality of life, life years and money. We quantified
the participants’ time preferences, and fitted a variety of functional forms between
the time of delay and their discount rate. We followed a non-linear mixed regres-
sion modeling approach with heteroscedasticity correction. RESULTS: Non-linear
regression estimates indicated a power function as the most appropriate func-
tional form for the discount rate. High within-individual correlations were esti-
mated through the mixed-effect approach. Finally, a negative relation between the
time of delay and the variance of the discount rate was observed for all models.
CONCLUSIONS: The evidence collected in this study pinpoint to differential time
preference of society, with a stronger preference for the near rather than the dis-
tant future. Additionally the advantages of a non-linear mixed model approach
were illustrated in such data with high within-individual correlation. However,
inference that can be utilized for decision making in the Netherlands requires a
larger, more representative sample of the Dutch population. For that reason, a large
nation-wide survey has been recently set forth.
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OBJECTIVES: As part of the IFEDH (Innovative Framework for Evidence based De-
cision making in Healthcare) research project (FFG grant number 827347) a cost
effectiveness analysis of systematic population based screening for abdominal
aortic aneurysm (AAA) in Austria has to be performed. The modeling method se-
lection process is conducted in detail, taking into account the possible influence of
chronic disease, smoking and gender. METHODS: In parallel three different strat-
egies are performed. The first one is a non systematic literature research on AAA
screening modeling concepts in Europe. The second deals with modeling concepts
available in the research project, mainly Markov models, agent based modeling
techniques and System Dynamics. The third part deals with a data overview from
Austrian Health service providers, identifying risk factors to be taken into account
as well as literature research on this topic. Based on the described tasks an inter-
disciplinary group from the field of HTA, data quality assessment, mathematical
modeling and statistics choose the best suited modeling concept. RESULTS: Based
on the identified literature on AAA screening modeling, the analyzed situation
regarding smoking behavior and chronic diseases as well as technical classification
of the benefits of the different methods an agent based simulation model has been
chosen. Detailed modeling concepts are developed and the implementation phase
is started. Due to the bottom-up approach the original data can be implemented
without transformations, leading to higher reliability. CONCLUSIONS: The devel-
opment of modern modeling methods in the IFEDH project in advance as well as
setting up an interdisciplinary team leads to higher performance regarding overall
project working time, quality in the decision process and realization of an AAA
screening model for Austria. Agent based modeling techniques are identified as
most flexible and well suited in the Austrian context.
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Kaplan-Meier (KM) survival analysis forms a cornerstone of the oncology mod-
eller’s toolkit. KM time-to-event data is often utilised by decision analysts to inform
a range of oncology model inputs. These may include the probability of a patient
dying, progressing or ceasing treatment over the course of a model’s time horizon
(typically key determinants of the incremental QALY and cost associated with an
intervention). As KM data is often incomplete, extrapolation beyond the period
observed is generally required. Extrapolation of KM data in several recent NICE
technology appraisals has moved away from the mechanical application of statis-
tical functions on the basis of ‘best-statistical fit’ as determined by Akaike and
Bayesian Information Criterion (a method used by manufacturers in a range of
previous NICE appraisals) to the use of extrapolation informed by consideration of
cumulative hazard plots. OBJECTIVES: To demonstrate the use of cumulative haz-
ard plots, their interpretation and their ability to inform resource allocation and
research decisions in health care. METHODS: A series of blinded case studies of
oncology pharmaceutical interventions assessed in NICE’s STA program are pre-
sented. These case studies demonstrate the importance of appropriately consider-
ing cumulative hazard plots when assessing the cost-effectiveness of pharmaceu-
tical technologies in oncology. RESULTS: Appropriate interpretation of cumulative
hazard plots can 1) help inform rational, rather than mechanical, extrapolation of
survival data; 2) can assist an analyst in explaining the discordance between sta-
tistical functions found to be the ‘best-fit’ by traditional test-based approaches and
subsequent poor face validity when compared to observed data; and 3) can be
utilised to generate hypotheses that may be tested in future clinical research (par-
ticularly the assessment of the effectiveness and cost-effectiveness of restricted/
extended durations of treatment). CONCLUSIONS: Measured consideration of cu-
mulative hazard plots from both RCT and observational data is essential to inform
appropriate decision making in oncology.
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OBJECTIVES: To estimate the cost and Quality Adjusted Life Years of tirofiban,
abciximab and eptifibatide plus standard care versus standard care alone in ST-
elevated myocardial infarction and Non ST-elevated (NSTE) Acute Coronary Syn-
drome (ACS) in England and Wales. METHODS: A lifetime state transition model
was constructed to conduct a cost utility analysis comparing low dose (for first 30
minutes, 0.4mg per minute, followed by 0.1 micrograms per kg per minute there-
after) tirofiban, standard dose abciximab (initially 250 micrograms per kg, followed
by 125 nanograms per kg per minute thereafter) or standard dose eptifibatide (ini-
tially 180 micrograms per kg, followed by 2 micrograms per kg per minute) added to
standard care in two populations: primary percutaneous coronary angioplasty in
STEMI and an Early Invasive strategy in medium to high risk NSTE ACS. Relative
Risks of death, bleeding, myocardial infarction and urgent revascularisation came
from a systematic review. Probabilistic sensitivity analysis was performed.
RESULTS: In STEMI, tirofiban plus standard care dominated the other interventions
in both with or without future unrelated illness cost. The Incremental Cost Effec-
tiveness Ratio (ICER) versus standard care only varied from approximately £1150 to
£9,000. In NSTE ACS, eptifibatide plus standard care dominated the other interven-
tions: the CER versus standard care varied from £1100 without to £7700 with unre-
lated illness costs. CONCLUSIONS: The addition of tirofiban to standard care in
STEMI is likely to be cost effective when a low dose bolus was administered fol-
lowed by continuous low dose infusion during primary percutaneous coronary
angioplasty. In the medium to high risk NSTE ASC population, eptifibatide could be
cost effective. However, there is much uncertainty in many parameters in both
target groups, largely due to lack of randomised controlled trial evidence. We rec-
ommend consideration of further research, particularly larger trials.
PRM75
PARALLEL SETS AS INTERACTIVE VISUALIZATION APPROACH FOR ANALYZING
MARKOV MODELS
Urach C1, Piringer H2, Popper N3, Breitenecker F1
1Vienna University of Technology, Vienna, Austria, 2VRVis Zentrum für Virtual Reality und
Visualisierung Forschungs-GmbH, Vienna, Austria, 3Dwh Simulation Services, Vienna, Austria
OBJECTIVES: Common methods to visualize Markov states over time (e.g., Markov-
cycle trees or state probability graphs) do not scale well to many cycles and have
limitations concerning the perception of proportions. An objective of the IFEDH
research project (FFG grant number 827347) was to overcome these limits by inves-
tigating new visualization methods of Markov models and their results.METHODS:
Inspired by the “Parallel Coordinates”, an interactive technique called Parallel Sets
has been developed for visualizing multidimensional categorical data. The visual-
ization lays out axes in a parallel way where each axis represents one categorical
dimension. Within each axis, boxes represent the categories which are scaled ac-
cording to the respective frequencies. Applied to Markov Models, the categorical
dimensions correspond to the various cycles. Joint probabilities of categories from
adjacent axes are shown as parallelograms connecting the respective categories.
The parallelograms can be interpreted as the number of patients transiting from
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